Loading clinical trials...
Loading clinical trials...
FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Astellas Pharma Inc
NCT07589647 · Bipolar Disorder (BD)
NCT07366424 · Falls in the Elderly
NCT06226025 · Bipolar Disorder, Delayed Sleep-Wake Phase Disorder
NCT07140913 · Mania, Bipolar Disorder
NCT06920940 · Bipolar Disorder (BD), Bipolar Disorder NOS, and more
Site JP00024
Chiba
Site JP00023
Fukuoka
Site JP00025
Fukuoka
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions